A similar drug strategy could be applicable in cancer treatment in humans given the authors’ demonstration that ERK5 is frequently overexpressed in human sarcomas and that patients with elevated ERK5 have worse survival outcomes. This evidence concerns the gene MAPK7 and sarcoma.